- Drug Class: Topoisomerase I inhibitor; antineoplastic agent
- Indications:
- Ovarian cancer (after failure of initial chemotherapy)
- Small cell lung cancer (SCLC)
- Cervical cancer (in combination with cisplatin)
- Mechanism of Action:
- Formulations:
- Intravenous: Powder or solution
- Oral capsules: 0.25 mg and 1 mg
- Dosing Considerations:
- Adjust for renal function
- Monitor hematologic parameters closely due to risk of myelosuppression
- Common Adverse Effects:
- Neutropenia, thrombocytopenia, anemia
- Nausea, vomiting, diarrhea
- Fatigue, alopecia
- Clinical Notes:
- Often used after failure of first-line therapies
- Requires careful infection monitoring due to immunosuppression
Synonyms
Hycamtin

